Evidence map›Paper›PMID 35992620›Full record

ArticleCanadian liver journal2018

Serum immunoglobulin A levels and non-alcoholic fatty liver disease.

Evan Elias, Julia Uhanova, Qian Li, Manna Zhang, Gerald Minuk

Abstract read
In one paragraph

Article in Canadian liver journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Mini-review: Serum immunoglobulins and MASLD.Frontiers in immunology · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Evan EliasSection of Hepatology, Department of Medicine and 2 Department of Pharmacology and Therapeutics, University of Manitoba, John Buhler Research Centre, Winnipeg, Manitoba.
Julia UhanovaSection of Hepatology, Department of Medicine and 2 Department of Pharmacology and Therapeutics, University of Manitoba, John Buhler Research Centre, Winnipeg, Manitoba.
Qian LiSection of Hepatology, Department of Medicine and 2 Department of Pharmacology and Therapeutics, University of Manitoba, John Buhler Research Centre, Winnipeg, Manitoba.
Manna ZhangSection of Hepatology, Department of Medicine and 2 Department of Pharmacology and Therapeutics, University of Manitoba, John Buhler Research Centre, Winnipeg, Manitoba.
Gerald MinukSection of Hepatology, Department of Medicine and 2 Department of Pharmacology and Therapeutics, University of Manitoba, John Buhler Research Centre, Winnipeg, Manitoba.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Intestinal immunity, and immunoglobulin A (IgA) in particular, may play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The aim of this study was to document the prevalence of elevated serum IgA levels in NAFLD patients and determine whether the severity and course of NAFLD differs in those with elevated (E-IgA) versus normal (N-IgA) levels. Methods: A retrospective review of a clinical database containing demographic, laboratory, and histologic findings of adult NAFLD patients was undertaken. Liver biochemistry, model for end stage-liver disease (MELD) and Fib-4 scores served to document disease severity and progression. Results: Of 941 NAFLD study subjects, 254 (27%) had E-IgA at presentation. E-IgA patients were older, and had lower serum albumin levels and higher MELD scores than N-IgA patients. The percent of E-IgA patients with Fib-4 scores >3.25 (suggestive of cirrhosis) was also higher (25% vs. 5.5%, Conclusions: Elevated serum IgA levels are common in NAFLD patients and when present, are associated with more advanced disease. Patients with elevated serum IgA levels are also more likely to progress to cirrhosis than those with normal levels.

Indexed as

cirrhosishepatitisIgAimmunoglobulinsnon-alcoholic fatty liver diseasenon-alcoholic steatohepatitis

Identifiers

PMID35992620
PMCPMC9202761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.